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ABSTRACT Human male germ cell tumors (GCTs) result
from malignant transformation of premeiotic or early meiotic
germ cells and exhibit embryonal-like differentiation of the
three germinal layers. The genetic basis of orign and expres-
sion of differentiated phenotypes by GCTs are poorly under-
stood. Our recent cytogenetic analysis ofa large series ofGCTs
has shown that two chromosome 12 abnormalities, an iso-
chromosome for the short arm [i(12p)J and deletions in the long
arm [del(12q)], characterize these tumors, which led us to
suggest that the deletions represent loss of one or more candi-
date tumor suppressor genes whose products regulate the
normal proliferation of the spermatogonial stem cells. We
undertook a molecular mapping of the deletions by comparing
germ-line and tumor genotypes of eight polymorphic loci in
paired normal/tumor DNA samples from 45 GCT patients.
Analysis of loss of constitutional heterozygosity at these loci
revealed two regions offrequent loss (>40%), one at 12q13 and
the other at 12q22, identifying the sites of the postulated tumor
suppressor genes. One tumor (no. 143A) exhibited a homozy-
gous deletion of a region of 12q22, which included the MGF
gene. The KIT and MGF genes have been shown to play key
roles in embryonal and postnatal development of germ cells;
therefore, we evaluated their expression by Northern blot
analysis in a panel of three GCT cell lines and 24 fresh GCT
biopsies. Deregulated expression ofMGF and KIT, which was
discordant between seminomatous and nonseminomatous le-
sions, was observed.
Human male germ cell tumors (GCTs) make up a unique
biological system for the study of malignancy and differen-
tiation. They exhibit, to varying degrees, embryonal-like
differentiation of the three germinal layers (1). The genetic
basis of malignant transformation and expression of differ-
entiated phenotypes by the transformed cells are poorly
understood. Recent cytogenetic studies of GCTs have iden-
tified a number of nonrandom abnormalities that affect chro-
mosome 12. The most specific of these was an isochromo-
some for the short arm [i(12p)], which has been demonstrated
in >85% of GCTs, occurring in all described histologic
subsets (2). In a recent cytogenetic analysis of 65 consecu-
tively ascertained GCTs with clonal chromosome abnormal-
ities, we showed that i(12p), monosomy 12, and deletions in
the long arm of chromosome 12 [del(12q)] occur with fre-
quencies of 86%, 11%, and 20%6, respectively (2). These data
strongly suggested that frequent loss of genetic material on
12q characterizes the development of these tumors.
Specific chromosomal deletions affecting 13q14 in retino-
blastoma (3), llpl3 in Wilms tumor (4), and 5q21 in familial
adenomatous polyposis (5) have enabled the identification of
a class of genes whose deletion releases the cell from normal
regulation of proliferation, the so-called tumor suppressor
genes (6). The location of these genes has been identified at
the molecular level by detection of loss of constitutional
heterozygosity (LOH) for restriction fragment length poly-
morphisms (RFLPs) in the target chromosomal regions (7).
LOH, suggesting loss of such suppressor genes, has been
demonstrated in a number of solid tumor systems (6). To
define the region of common deletion in GCTs at the molec-
ular level, we compared the genotypes of germ-line and
tumor cell RFLPs at eight loci mapped to 12q in 45 patients.
These data showed patterns of LOH consistent with the
cytogenetic data (i.e., monosomy and deletion of 12q). In
addition, high frequencies of LOH identified two sites of
candidate tumor suppressor genes, one at 12q13 and the other
at 12q22 in these tumors.
The MGF gene product makes up the ligand for the
receptor encoded by the KITprotooncogene (reviewed in ref.
8). We recently mapped MGF to 12q22 (9), the site of one of
the candidate tumor suppressor genes identified in this study.
We therefore evaluated three established GCT cell lines and
a panel of 24 GCT tumor biopsies for expression ofMGF and
KIT genes by Northern blot analysis and found deregulated
expression of both genes.
MATERIALS AND METHODS
Tumor and Normal Tissues and Cell Lines. The tumor
samples and the peripheral blood samples to establish con-
stitutional genotypes were obtained from patients evaluated
at The Memorial Sloan-Kettering Cancer Center as de-
scribed (2). Tumor biopsy and corresponding peripheral
blood samples from 45 patients were used in the LOH study.
These tumors were drawn from all histologic subgroups and
were composed of 4 seminomas and 41 nonseminomas (11
teratomas, 14 embryonal carcinomas, 3 yolk sac tumors, 1
choriocarcinoma, 1 teratoma with neuroectodermal differen-
tiation, and 11 tumors of mixed histology with various
nonseminomatous elements). DNA analysis for LOH was
performed on frozen tissue determined to be essentially
tumor by examination of cryostat preparations. For RNA
analysis, two previously established nonseminomatous cell
lines (NT2/D1 and N2102ep), one nonseminomatous cell line
recently established by us (240A), and a panel of 24 fresh
GCT tumors were utilized. The samples were derived from 10
seminomas, 12 nonseminomas, and 2 combined (seminoma-
tous and nonseminomatous elements) tumors. Ten of these
tumors also were included in the panel assayed for LOH by
RFLP analysis.
Southern and Northern Blot Analysis. For Southern blot
analysis, 6-10 gg ofDNA (normal and tumor) digested with
the appropriate restriction enzyme (Taq I, Msp I, and Pst I)
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was electrophoresed in 0.8% agarose gels, transferred to
nylon membranes, and hybridized with 32P-labeled probes
following standard methods. The hybridized filters were read
on a Betascope (Betagen) for direct quantitation of signal
intensity of allelic bands. Reduction in the signal intensity of
an allele by >45% ofthe signal from the germ-line allele (after
adjusting for variation in DNA loading) was considered as
evidence of LOH. Such losses ranged from 48% to 100%,
with the majority exhibiting >60o loss.
For Northern blot analysis ofKIT andMGF expression, 10
,ug of total RNA from each tumor was electrophoresed in a
1% agarose/3% formaldehyde gel, transferred to a nylon
membrane, and hybridized with [a-32P]dCTP-labeled KIT
and MGF cDNA probes.
The probes used in this study consisted ofeight polymorphic
(D12S4, D12S6, D12S7, D12S8, D12S12, D12S14, D12S15,
and D12S17) and three nonpolymorphic (MGF, IGF1, and
IAPP) loci recently mapped by us to specific bands on 12q by
using the fluorescence in situ hybridization method (Table 1)
and a cDNA probe for KIT mapped to 4q (22). In addition,
probes for the JH region of the immunoglobulin heavy-chain
gene (IGH) (23) and D14S20 (pMCOC12), both localized on
14q, were used as reference probes for normalization ofDNA
loading in quantitation of signals from the polymorphic probes
used in the LOH assay. The JH probe was a gift from J.
Ravetch and the D14S20 probe was obtained from the Amer-
ican Type Culture Collection (ATCC).
RESULTS
Analysis of LOH on 12q. We evaluated 45 tumor DNA
samples from 45 patients for allelic losses at eight polymor-
phic loci mapped to 12q. Except 1 case (no. 185A), all cases
were informative for one or more loci (heterozygosity of
alleles in the germ line). LOH in tumor DNA compared to
germ-line DNA was seen for at least one locus in 22 cases
(Fig. 1), whereas the remaining tumor DNAs exhibited no
loss at any informative loci. One germ-line allele was lost at
all the informative loci in three tumors (nos. 143A, 186B, and
239A), suggesting monosomy for 12q (Fig. 1). Although
cytogenetic data were not available for these three tumors,
two (186B and 239A) were evaluated for chromosome 12 and
i(12p) copy number by fluorescence in situ hybridization
analysis of interphase cells using a probe for the centromeric
a-satellite DNA by a method recently described by us (24).
By this assay, tumor 186B had one to three copies of normal
chromosome 12 and one or two copies of i(12p) per cell,
whereas tumor 239A had one to six copies of normal chro-
mosome 12 and one to five copies of i(12p) per cell, suggest-
ing that the multiple copies of chromosome 12 resulted from
nondisjunctional loss of one parental copy followed by gain
of the other (25).
Table 2 summarizes the data on allelic loss in the tumors
evaluated, and Fig. 2 illustrates representative Southern
blots. Among the probes tested, D12S6, D12S7, and D12S12
showed high (>40%o) frequency losses (Table 2). D12S6 has
been mapped to 12q13.3, whereas D12S7 and D12S12 have
been mapped to 12q22 (Table 1). These data suggested that
the distal region of band 12q13 and the region 12q22-qter
harbor two candidate tumor suppressor genes (Fig. 1). Un-
fortunately, no polymorphic probes have currently been
mapped to the region distal to 12q22, which precluded
determination of the distal limit of the deletion by the RFLP
assay.
Evidence for Interstitial Deletion in 12q22 in Tumor 143A.
As described above, tumor 143A, a seminoma, was one of
three tumors in which the LOH data indicated loss of one
germ-line copy of 12q, leading to genetic monosomy. RFLP
analysis oftumorDNA revealed no signal forD12S7 at 12q22
(Fig. 3). D12S6 at 12ql3.2-13.3 exhibited loss of one allele,
whereas the remaining polymorphic loci were uninformative
and exhibited signal consistent with a single copy of each of
these loci by quantitation of signal intensity (Fig. 3). To
establish the limits of the 12q deletion in this tumor, hybrid-
izations were performed with probes for MGF and D12S12,
both of which have also been mapped to 12q22, the closest
mapped proximal gene IAPP (12q21-22), and the closest
mapped distal gene IGF1 (12q23) (Table 1). These hybrid-
izations showed that MGF was homozygously deleted while
IAPP, D12S12, and IGFI were retained, consistent with
presence of one copy of chromosome 12. These data, as
shown in Fig. 3, clearly demonstrated an interstitial deletion
in the 12q22 region, which included MGF and D12S7 in the
single retained chromosome in this tumor. Southern blot
analysis ofDNA from 89 GCTs using theMGFcDNA probe,
however, did not reveal rearrangements or additional cases of
homozygous deletions (data not shown).
Expression of MGF and KIT Is Deregulated in GCTs. The
above data suggested that loss of function of MGF and/or
another gene in the 12q22 region may be one ofthe key events
in the development of GCTs. To test for MGF and KIT
expression, RNA isolated from 3 GCT cell lines and 24 fresh
GCTs was subjected to Northern blot analysis using MGF
and KIT cDNA as probes. As shown in Table 3 and Fig. 4,
1 of the 3 teratocarcinoma cell lines, 1 of the 10 seminomas,
and 6 of the 12 nonseminomas showed MGF expression. In
contrast, KIT expression was noted in 3 seminomas while
none of the teratocarcinoma cell lines and nonseminomatous
and combined tumor biopsies expressed KITmRNA. Only 1
seminoma (no. 157A) expressed both KIT and MGF. Among
the 24 GCT tissues studied for MGF expression, 10 were also
evaluated for LOH on 12q. MGFmRNA was detected in 5 of
these. Of these 10 tumors, 2 were informative for D12S7
localized to 12q22-namely, 155B, which expressed MGF,
Table 1. Probes used and their chromosomal map positions
Previous Map position
Probe Locus Source Ref. map position Ref. by FISH
pCMM1.2 D12S15 ATCC 10 12q 10 12q12-13.1
pYNH15 D12S17 ATCC 11 12q 11 12q13.1
pEFD33.2 D12S14 ATCC 12 12q 12 12q13
p9Fll D12S4 ATCC 13 12qcen-ql4 13 12q13
11-1-7 D12S6 M. Litt 14 12qcen-ql3 14 12ql3.2-13.3
p7Gll D12S8 ATCC 13 12ql4-qter 15 12q14-15
pDL32B D12S7 ATCC 16 12ql4.3-qter 16 12q22
pAC230 D12S12 I. Balazs 17 12q 17 12q22
pHKITL MGF W.H. 12q22-24 18 12q22
phigfl IGFI ATCC 19 12q23 15 12q23
scIAP8 IAPP J. Hoppener 20 12cen-q21.1 21 12q21-22
FISH, fluorescence in situ hybridization (9).
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FIG. 1. Map of LOH on 12q in 22 GCTs showing allelic losses with one or more probes. Only tumors with heterozygosity of at least one
locus are represented. Probe map positions in relation to the ideogram are as listed in Table 1. Filled circles indicate allelic loss, crosshatched
circles indicate retention of germ-line heterozygosity, and open circles indicate germ-line homozygosity.
and 235A, which did not express MGF. Both tumors retained
germ-line heterozygosity.
DISCUSSION
Male GCTs retain both X and Y chromosomes and hence
arise in premeiotic to early meiotic cells (i.e., in spermato-
genic cells in stages ofdevelopment from type A spermatogo-
nia to spermatocytes prior to anaphase I of meiosis). Recent
molecular studies of mammalian gametogenesis have shown
that both spermatogenesis and oogenesis are characterized
by unique patterns of expression of a wide array of cellular
protooncogenes (26). Notably, Fos, Jun, and Myc were
shown to be specifically expressed at high levels in murine
type B spermatogonia (27), a stage that ushers in a major shift
in developmental program (i.e., initiation of meiosis and
cessation of further mitotic division by the spermatocyte).
Malignant transformation blocks entry or continuation of
these cells in meiosis and precipitates a program of unlimited
mitotic proliferation.
Our previous cytogenetic data (2) and the molecular data
presented here establish i(12p) and del(12q) to be consistently
associated with all histologic subsets of GCTs. We have
previously shown that i(12p) probably arises from centro-
meric exchanges in homologous chromosomes (24); there-
fore, it is etiologically unrelated to the deletions in the long
arm and possibly represents a second event in the genesis of
these tumors. We further showed that, molecularly, the
deletions cluster in two regions, 12q13 and 12q22. The losses
observed displayed different patterns of minimal region in-
Table 2. LOH frequency of polymorphic loci on 12q
Polymorphic Cases Informative Cases with LOH
locus studied cases No. Percent
D12SJ5 45 14 1 7
D12S17 45 26 7 27
D12S14 45 19 3 16
D12S4 44 23 4 17
D12S6 44 17 7 41
D12S8 44 8 1 13
D12S7 41 19 8 42
D1252 43 15 7 47
volvement-individual tumors exhibited loss of proximal,
distal, or both regions (Fig. 1).
LOH indicating loss of candidate tumor suppressor genes
has been documented in a number of specific regions in the
human genome in specific tumor types (6). In the case of
chromosome 12, only one previous study indicated LOH, in
the region distal to 12q24, in a high proportion of gastric
adenocarcinomas (28). To our knowledge, the deletions de-
tected by us in GCTs have previously not been reported in
this or other tumor systems and probably identify sites of
candidate tumor suppressor genes specific to GCTs. Of note
in this regard is the detection by us ofa homozygous deletion
in the 12q22 region in tumor 143A, which offers the oppor-
tunity to isolate the deleted gene.
The proximal deleted region in GCTs, 12q13.3, has previ-
ously been shown to be associated with frequent transloca-
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FIG. 2. Allelic deletions in 12q illustrated by Southern blots of
probe hybridizations with D12S17 and D12S6 (12q13) as well as
D12S7 and D12S12 (12q22). D12S17, D12S6, and D12S12 hybridiza-
tions were performed after digestion of DNA with Msp I, whereas
D12S7 hybridization was performed after digestion ofDNA with Taq
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FIG. 3. Homozygous deletion in 12q22 in tumor 143A. Results of
hybridization to probes mapped along 12q (Table 1) are shown.
D12S6 shows heterozygous loss, whereas D12S7 and MGF show
homozygous loss in the tumor () compared to the germ line (N). The
remaining probes show reduced signal intensity in the tumor com-
pared to the germ line, consistent with the presence of a single copy
of chromosome 12. Hybridizations with D12S15, D12S17, D12S6,
and D12S8 were to DNAs digested with Msp I, whereas hybridiza-
tions with D12S4, D12S14, IAPP, MGF, D12S7, and IGFI were to
DNAs digested with Taq I. Control hybridizations of the same filter
with the chromosome 14 probes D14S20 (Msp I) and IGH/JH (Taq
I) indicate equal loading of normal and tumor DNA.
tion in benign and malignant adipose tissue tumors. Thus,
40% of benign lipomas exhibit chromosome rearrangements
affecting the 12q13-14 region with variable reciprocal part-
ners (29), whereas virtually 100% ofmyxoid liposarcomas are
characterized by the t(12;16)(q13;pll) translocation (30). The
INT] (WNTJ), GLI, and MDM2 genes have been mapped to
the 12ql3-ql4 region (31-33). While neither INTl nor GLI
were seen to be rearranged in myxoid liposarcomas by
Southern blot analysis (34), pulsed field mapping of 600
kilobases of DNA surrounding the GLI locus showed a
specific alteration in the restriction pattern due to methyl-
ation differences unique to myxoid liposarcomas (35). MDM2
has been shown to be amplified and/or overexpressed in soft
tissue sarcomas (33). However, we did not find any genomic
alteration ofINTJ, GLII, orMDM2 in male germ cell tumors
(data not shown).
Apart from the putative tumor suppressor gene suggested
by our results, the only gene of potential relevance to
oncogenesis mapped to the distal deleted region, 12q22, as
previously noted, is MGF. MGF encodes the ligand for the
KITprotooncogene, a tyrosine kinase growth factor receptor
that exhibits primary sequence homology with colony-
stimulating factor type 1 and platelet-derived growth factor
receptors and also is homologous to the viral oncogene v-kit
(22, 36). KIT and MGF have been shown to be the structural
loci for the murine W and SI loci, respectively; mutations at
both loci affect normal development of primordial germ cells,
hematopoietic stem cells, and melanocytes (37-41). The
expression patterns ofKIT and MGF in migrating embryonal
cells is consistent with a role in homing mechanisms of
hematopoietic cells, germ cells, and melanoblasts (42, 43). In
the postnatal murine testis, in situ hybridization studies
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ing from Al spermatogonia to preleptotene spermatocytes,
and in Leydig cells, suggesting a role for this gene in
spermatocyte differentiation as well (44). The expression
pattern of MGF in postnatal testes is less well known,
although one study by Northern blot analysis suggested
expression in Sertoli cells but not in germ cells (45). With
regard to GCTs, although studies ofMGF expression have
not been reported to date to our knowledge, one recent study
observed KIT to be expressed in 80% of seminomas and 7%
of nonseminomas (46). In this study, we noted deregulated
and discordant expression of both genes. KITwas expressed
in 30%o of the seminomas but in none of the nonseminomas,
whereas MGF was expressed in 3% of the seminomas and
50%6 of the nonseminomas. The basis for this pattern of
expression currently is unknown. It may represent a dereg-
ulated expression of the constitutional phenotype of the
precursor cells or de novo expression by the transformed
cells. The relationship, if any, between the deregulated
expression of MGF and the function of the putative tumor
suppressor gene in the 12q22 region also needs to be inves-
tigated.
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